Magaret Macro
Impact in
- Hematology top 0.05%
- Multiple Myeloma Research and Treatments
- Oncology top 0.5%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
Papers in
- Hematology 126
- Multiple Myeloma Research and Treatments 120
- Oncology 60
- Cancer Treatment and Pharmacology 25
- Peptidase Inhibition and Analysis 22
- Co-authors
- Gérald Marit (3 shared papers)Bertrand Coiffier (4 shared papers)Hervé Tilly (4 shared papers)Dominique Bordessoule (2 shared papers)Karim Belhadj (8 shared papers)Sylvie Castaigné (3 shared papers)Catherine Thieblemont (4 shared papers)Christophe Fermé (3 shared papers)
- Journals
- Blood (51 papers)Journal of Clinical Oncology (11 papers)Leukemia (9 papers)Haematologica (7 papers)HemaSphere (7 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Magaret Macro
164 papers receiving 10.6k citations
Magaret Macro's Hit Papers
Peers
Comparison fields: 5 of 98
- Hematology 7.5k
- Oncology 4.5k
- Genetics 1.5k
- Pathology and Forensic Medicine 2.0k
- Molecular Biology 5.0k
Countries citing papers authored by Magaret Macro
This map shows the geographic impact of Magaret Macro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magaret Macro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magaret Macro more than expected).
Fields of papers citing papers by Magaret Macro
This network shows the impact of papers produced by Magaret Macro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magaret Macro. The network helps show where Magaret Macro may publish in the future.
Co-authors
The 25 scholars most cited alongside Magaret Macro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 173 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Hit paper breakdown → | 2010 | 1236 |
| 2 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma Hit paper breakdown → | 2017 | 977 |
| 3 | Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma Hit paper breakdown → | 2019 | 778 |
| 4 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 769 |
| 5 | 1998 | 435 | |
| 6 | Treatment of Older Patients with Mantle-Cell Lymphoma Hit paper breakdown → | 2012 | 402 |
| 7 | 2010 | 363 | |
| 8 | 2018 | 349 | |
| 9 | 2005 | 329 | |
| 10 | Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 274 |
| 11 | 2017 | 264 | |
| 12 | 2016 | 224 | |
| 13 | 2003 | 214 | |
| 14 | 2012 | 191 | |
| 15 | 2009 | 188 | |
| 16 | 2019 | 180 | |
| 17 | 2013 | 177 | |
| 18 | 2019 | 144 | |
| 19 | 2021 | 139 | |
| 20 | 2020 | 107 |
About Magaret Macro
Magaret Macro is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Pathology and Forensic Medicine, having authored 173 papers that have together received 10.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (120 papers), Protein Degradation and Inhibitors (43 papers), Cancer Treatment and Pharmacology (25 papers), Peptidase Inhibition and Analysis (22 papers), Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (11 papers). The work is most often cited by research in Hematology (7.5k citations), Oncology (4.5k citations), Genetics (1.5k citations), Pathology and Forensic Medicine (2.0k citations) and Molecular Biology (5.0k citations). Magaret Macro has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Gérald Marit, Bertrand Coiffier, Hervé Tilly, Dominique Bordessoule, Karim Belhadj, Sylvie Castaigné, Catherine Thieblemont, Christophe Fermé, Éric Van Den Neste and Isabelle Plantier. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Haematologica and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.